<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01933048</url>
  </required_header>
  <id_info>
    <org_study_id>IDCRP-070</org_study_id>
    <nct_id>NCT01933048</nct_id>
  </id_info>
  <brief_title>Self-Administered Nasal Influenza Feasibility Study</brief_title>
  <acronym>SNIF</acronym>
  <official_title>Self-Administered Nasal Influenza Vaccine: Immunogenicity and Feasibility of Group Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uniformed Services University of the Health Sciences</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uniformed Services University of the Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective, open-label clinical trial is to evaluate the immunogenicity
      of self-administered (SA) live, attenuated influenza vaccine (LAIV) in comparison with
      healthcare worker administered (HCWA) LAIV and to evaluate the feasibility of group
      self-administration of LAIV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase IV, open-label, prospective clinical trial assesses SA-LAIV, testing whether the
      immunogenicity of SA-LAIV is non-inferior to that of HCWA-LAIV, as well as evaluating the
      feasibility of utilizing group administration for SA-LAIV. Subjects will be enrolled into one
      of two major treatment arms: HCWA-LAIV (Estimated N = 550) and SA-LAIV (Estimated N = 550).
      Enrollment into each major treatment arm will be stratified by study site. Enrollment in the
      HCWA-LAIV and SA-LAIV treatment arms may occur concurrently at each site. Subjects enrolling
      in the study will be randomized to HCWA or SA, and within the SA arm to either individual
      self-administration, or group administration. Specifically, following self-administration of
      LAIV to 190 individual subjects, 180 subjects will be vaccinated in 36 groups of 5 and 180
      subjects will be vaccinated in 18 groups of 10. All vaccinations in the SA-LAIV arm will be
      given under the direction and supervision of a research staff member who is trained to
      administer LAIV vaccines. Following immunization all subjects will return for one visit at
      approximately 28 (± 7) days for follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-vaccination Geometric Mean Titer (GMT) Ratios Between HCWA and SA Subjects</measure>
    <time_frame>28+/- 7 days post-vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference and Proportion in Seroresponse of Subjects</measure>
    <time_frame>28+/- 7 days post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference and Proportion in Seroconversion of Subjects</measure>
    <time_frame>28+/- 7 days post-vaccination</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Feasibility of Self-administration Prior to Vaccine Administration</measure>
    <time_frame>28+/- 7 days post-vaccination</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Feasibility of Self-administration Following Vaccine Administration</measure>
    <time_frame>28+/- 7 days post-vaccination</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1077</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Healthcare Worker Administration</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FluMist administered by a Healthcare Worker</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Self-Administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FluMist self-administered by subject</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FluMist</intervention_name>
    <description>FluMist Intranasal Vaccine</description>
    <arm_group_label>Healthcare Worker Administration</arm_group_label>
    <arm_group_label>Self-Administration</arm_group_label>
    <other_name>influenza virus vaccine LAIV4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or healthy, non-pregnant females

          -  18-49 years of age

          -  Department of Defense beneficiary including active duty members

          -  Able to speak and understand English, and provide written informed consent

        Exclusion Criteria:

          -  Known hypersensitivity to eggs, egg-proteins, gentamicin, gelatin, or arginine or
             life-threatening reactions to previous influenza vaccination

          -  Prior receipt of the 2012-2013 seasonal influenza vaccine for 2012-2013 season or
             prior receipt of the 2013-2014 seasonal influenza vaccine for 2013-2014 season

          -  Known clinical diagnosis of reactive airway disease, wheezing, or asthma (excluding
             exercise-induced asthma)

          -  Reported febrile upper respiratory illness (oral or tympanic temperature greater than
             100°F or a subjective fever) at the time of or within the 24 hours prior to
             immunization

          -  Known to be pregnant, possibly pregnant or breast-feeding

          -  Known diagnosis of human immunodeficiency virus (HIV) infection, chronic active
             hepatitis B infection, or chronic hepatitis C infection

          -  History of Guillain-Barre Syndrome

          -  Household member known to be immunocompromised (either a known disease or disorder
             such as HIV, or other acquired or congenital immunodeficiency disorder, or taking
             systemic steroids (any dose) or high daily dose inhaled steroids, tumor necrosis
             factor-alpha inhibitors, or monoclonal antibodies used to treat autoimmune disease)

          -  Receipt of medications with activity against influenza A and/or B (ex: Tamiflu®,
             Relenza®, amantadine, or rimantadine) within 48 hours prior to vaccine administration

          -  Use of any oral or intravenous systemic steroids (any dose) or any daily dose inhaled
             steroids

          -  At the time of enrollment, any person who is trained to administer intranasal vaccines
             or who has been involved in any recurring role associated with the administration of
             intranasal vaccines to others in the clinic or military treatment facility (MTF)

          -  Prior participation in this research study

          -  Any acute or chronic medical condition that, in the opinion of the investigator, would
             render vaccination unsafe, interfere with the evaluation of responses, or render the
             subject unable to meet the requirements of the protocol. These conditions may include,
             but are not limited to: history of significant renal impairment (dialysis and
             treatment for kidney disease, including diabetic and hypertensive kidney disease);
             poorly controlled diabetes mellitus or patients with diabetes mellitus on insulin
             (subjects with well-controlled diabetes mellitus on oral agents may enroll as long
             there has been no dosage increase within the past 6 months); cardiac insufficiency, if
             heart failure is present; an arteriosclerotic event during the 6 months prior to
             enrollment (e.g., history of myocardial infarction, stroke, recanalization of femoral
             arteries, or transient ischemic attack).

          -  If the individual received a live virus vaccine (e.g., Varicella,
             Measles-Mumps-Rubella, Yellow Fever, Smallpox) in the past 4 weeks, they should wait
             28 days before receiving LAIV. There is no reason to defer vaccination if the
             individual was vaccinated with an inactivated vaccine or if they have recently
             received blood or other antibody-containing blood products.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Burgess, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Uniformed Services University of the Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Naval Medical Center San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Military Health System</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2013</study_first_submitted>
  <study_first_submitted_qc>August 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2013</study_first_posted>
  <results_first_submitted>March 28, 2016</results_first_submitted>
  <results_first_submitted_qc>August 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 12, 2017</results_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uniformed Services University of the Health Sciences</investigator_affiliation>
    <investigator_full_name>Timothy Burgess, MD, MPH</investigator_full_name>
    <investigator_title>Captain, Medical Corps, US Navy</investigator_title>
  </responsible_party>
  <keyword>influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Sharing of individual participant data (IPD) would require revisions and additional regulatory approval, that will not be pursued.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment and enrollment was conducted in San Antonio, Texas and San Diego, California.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Healthcare Worker Administration (HCWA)</title>
          <description>FluMist administered by a Healthcare Worker</description>
        </group>
        <group group_id="P2">
          <title>Self-Administration (SA)</title>
          <description>FluMist self-administered by subject</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="548"/>
                <participants group_id="P2" count="529"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="523"/>
                <participants group_id="P2" count="501"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>personal reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>unknown reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthcare Worker Administration</title>
          <description>FluMist administered by a Healthcare Worker</description>
        </group>
        <group group_id="B2">
          <title>Self-Administration</title>
          <description>FluMist self-administered by subject</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="523"/>
            <count group_id="B2" value="501"/>
            <count group_id="B3" value="1024"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" lower_limit="26" upper_limit="38"/>
                    <measurement group_id="B2" value="28" lower_limit="24" upper_limit="36"/>
                    <measurement group_id="B3" value="29" lower_limit="25" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="298"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="366"/>
                    <measurement group_id="B2" value="360"/>
                    <measurement group_id="B3" value="726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="204"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="420"/>
                    <measurement group_id="B2" value="400"/>
                    <measurement group_id="B3" value="820"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="332"/>
                    <measurement group_id="B2" value="347"/>
                    <measurement group_id="B3" value="679"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="523"/>
                    <measurement group_id="B2" value="501"/>
                    <measurement group_id="B3" value="1024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post-vaccination Geometric Mean Titer (GMT) Ratios Between HCWA and SA Subjects</title>
        <time_frame>28+/- 7 days post-vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthcare Worker Administration</title>
            <description>FluMist administered by a Healthcare Worker</description>
          </group>
          <group group_id="O2">
            <title>Self-Administration</title>
            <description>FluMist self-administered by subject</description>
          </group>
        </group_list>
        <measure>
          <title>Post-vaccination Geometric Mean Titer (GMT) Ratios Between HCWA and SA Subjects</title>
          <units>titer ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="523"/>
                <count group_id="O2" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8" lower_limit="41.1" upper_limit="51.1"/>
                    <measurement group_id="O2" value="48.7" lower_limit="43.6" upper_limit="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" lower_limit="40.8" upper_limit="50.6"/>
                    <measurement group_id="O2" value="46.4" lower_limit="41.6" upper_limit="51.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" lower_limit="15.9" upper_limit="18.6"/>
                    <measurement group_id="O2" value="17.8" lower_limit="16.5" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane (2013-2014 only; HCWA n=346; SA n=359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" lower_limit="14.7" upper_limit="17.9"/>
                    <measurement group_id="O2" value="14.7" lower_limit="13.3" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A/H1N1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>non-inferiority</non_inferiority_desc>
            <p_value>0.43</p_value>
            <method>Farrington-Manning Method</method>
            <method_desc>based on margin of 0.05</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A/H3N2</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>non-inferiority</non_inferiority_desc>
            <p_value>0.80</p_value>
            <method>Farrington-Manning Method</method>
            <method_desc>based on margin of 0.05</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>B/Yamagata</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>non-inferiority</non_inferiority_desc>
            <p_value>0.55</p_value>
            <method>Farrington-Manning Method</method>
            <method_desc>based on margin of 0.05</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>B/Brisbane</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>non-inferiority</non_inferiority_desc>
            <p_value>0.16</p_value>
            <method>Farrington-Manning Method</method>
            <method_desc>based on margin of 0.05</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference and Proportion in Seroresponse of Subjects</title>
        <time_frame>28+/- 7 days post-vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthcare Worker Administration</title>
            <description>FluMist administered by a Healthcare Worker</description>
          </group>
          <group group_id="O2">
            <title>Self-Administration</title>
            <description>FluMist self-administered by subject</description>
          </group>
        </group_list>
        <measure>
          <title>Difference and Proportion in Seroresponse of Subjects</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="523"/>
                <count group_id="O2" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="340"/>
                    <measurement group_id="O2" value="344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="335"/>
                    <measurement group_id="O2" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane (2013-2014 only; HCWA n=346; SA n=359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference and Proportion in Seroconversion of Subjects</title>
        <time_frame>28+/- 7 days post-vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthcare Worker Administration</title>
            <description>FluMist administered by a Healthcare Worker</description>
          </group>
          <group group_id="O2">
            <title>Self-Administration</title>
            <description>FluMist self-administered by subject</description>
          </group>
        </group_list>
        <measure>
          <title>Difference and Proportion in Seroconversion of Subjects</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="523"/>
                <count group_id="O2" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane (2013-2014 only; HCWA n=346; SA n=359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Feasibility of Self-administration Prior to Vaccine Administration</title>
        <time_frame>28+/- 7 days post-vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthcare Worker Administration (HCWA)</title>
            <description>FluMist administered by a Healthcare Worker
FluMist: FluMist Intranasal Vaccine
Health care worker-administered (HCWA; n=523)</description>
          </group>
          <group group_id="O2">
            <title>Self-Administration (SA)</title>
            <description>FluMist self-administered by subject
FluMist: FluMist Intranasal Vaccine
Self-administered (SA)/singleton (n=178), SA/groups of 5 (n=163), and SA/groups of 10 (n=160).</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility of Self-administration Prior to Vaccine Administration</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="523"/>
                <count group_id="O2" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HCWA preferred method</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SA preferred method</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No preference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320"/>
                    <measurement group_id="O2" value="307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Feasibility of Self-administration Following Vaccine Administration</title>
        <time_frame>28+/- 7 days post-vaccination</time_frame>
        <population>Numbers include participants randomized to the SA group only.</population>
        <group_list>
          <group group_id="O1">
            <title>Self-Administration (SA)</title>
            <description>FluMist self-administered by subject
FluMist: FluMist Intranasal Vaccine
Self-administered (SA)/singleton (n=178), SA/groups of 5 (n=163), and SA/groups of 10 (n=160).</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility of Self-administration Following Vaccine Administration</title>
          <population>Numbers include participants randomized to the SA group only.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HCWA preferred method</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SA preferred method</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No preference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Healthcare Worker Administration</title>
          <description>This group includes healthcare worker administration of FluMist to subjects.</description>
        </group>
        <group group_id="E2">
          <title>Self-Administration</title>
          <description>This group includes subjects who self-administered FluMist.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="548"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="529"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <description>Not related to procedure. Relatedness=unrelated</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="548"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="529"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <description>Hospitalized overnight for hematoma after lipoma excision. Not related to procedure. Relatedness=unrelated.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="548"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="529"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <description>Hospitalization; chest/abdominal wall herniation from previous injury. Not related to procedure. Relatedness=unrelated.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="548"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="529"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <description>Hospitalized 4 days for pulmonary embolism. Not related to procedure. Relatedness=not probable.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="548"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="529"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <description>Hospitalized 4 days for deep vein thrombosis. Not related to procedure. Relatedness=not probable.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="548"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="529"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="548"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="529"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="548"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="529"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="548"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="529"/>
              </event>
              <event>
                <sub_title>Tiredness and weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="548"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="529"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="548"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="529"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal and chest congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="548"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="529"/>
              </event>
              <event>
                <sub_title>Sinusitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="548"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="529"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="548"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="529"/>
              </event>
              <event>
                <sub_title>Cough and sore throat</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="548"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="529"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="548"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="529"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Related to blood draw. Relatedness=definitely.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="548"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="529"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Subjects were not followed for clinical outcomes during the influenza season.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Eugene V. Millar, PhD</name_or_title>
      <organization>Uniformed Services University of the Health Sciences</organization>
      <phone>301-816-8451</phone>
      <email>emillar@idcrp.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

